诺和锐与生物合成人胰岛素对妊娠期糖尿病患者Cys C、HCY及妊娠结局的影响

Effects of NovoRapid and biosynthetic human insulin on Cys C,HCY and pregnancy outcomes in patients with gestational diabetes mellitus

目的探讨诺和锐与生物合成人胰岛素(诺和灵-R)对妊娠期糖尿病(GDM)孕妇血清胱抑素C(Cys C)、同型半胱氨酸(HCY)及妊娠结局的影响比较。方法选取2017年2月至2018年12月荆门市第二人民医院收治的216例GDM孕妇的临床资料,按随机数字表法分为观察组(n=112)和对照组(n=104)。观察组患者接受诺和锐治疗,对照组患者则接受诺和灵-R治疗。结果观察组患者血糖达标时间明显短于对照组患者(P<0.05);治疗后,观察组患者FPG、2hPG、HbA1c水平均明显低于对照组患者(P<0.05);治疗后,观察组患者血清Cys C、HCY水平较治疗前明显降低,且显著低于对照组患者(P<0.05);观察组患者妊娠期并发症、围生儿并发症发生率明显低于对照组(P<0.05)。结论诺和锐治疗GDM的疗效优于诺和灵-R,可更好地控制血糖水平,降低血清Cys C、HCY水平,改善妊娠结局,值得临床推广应用。

Objective To investigate the effects of NovoRapid and biosynthetic human insulin(Novolin-R)on serum cystatin C(Cys C)and homocysteine(HCY)and pregnancy outcome in pregnant women with gestational diabetes mellitus(GDM).Methods A total of 216 cases of GDM pregnant women admitted to our hospital from February 2017 to December 2018 were selected.The patients were divided into observation group(n=112)and control group(n=104)according to the random number table method.Patients in the observation group received NovoRapid treatment,and patients in the control group received Novolin-R treatment.Results The blood glucose compliance time of observation group was significantly shorter than that of control group(P<0.05).After treatment,the PG,2hPG and HbA1c levels of observation group were significantly lower than those of control group(P<0.05).After treatment,the serum Cys C and HCY levels of observation group were significantly lower than those before treatment,and were significantly lower those of control group(P<0.05).The incidence of gestational complication and neonatal complication of observation group were significantly lower than those of control group(P<0.05).There was no significant difference on cesarean section rate between the two groups(P>0.05).Conclusion The efficacy of NovoRapid in the treatment of GDM is better than Novolin-R,which could better control blood glucose levels,reduce serum Cys C and HCY levels,and improve pregnancy outcomes.The NovoRapid treatment is worthy of clinical promotion and application.